These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24712972)

  • 1. Mind the gaps--the epidemiology of poor-quality anti-malarials in the malarious world--analysis of the WorldWide Antimalarial Resistance Network database.
    Tabernero P; Fernández FM; Green M; Guerin PJ; Newton PN
    Malar J; 2014 Apr; 13():139. PubMed ID: 24712972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.
    Ozawa S; Evans DR; Higgins CR; Laing SK; Awor P
    Malar J; 2019 Jan; 18(1):5. PubMed ID: 30626380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority.
    Newton PN; Green MD; Mildenhall DC; Plançon A; Nettey H; Nyadong L; Hostetler DM; Swamidoss I; Harris GA; Powell K; Timmermans AE; Amin AA; Opuni SK; Barbereau S; Faurant C; Soong RC; Faure K; Thevanayagam J; Fernandes P; Kaur H; Angus B; Stepniewska K; Guerin PJ; Fernández FM
    Malar J; 2011 Dec; 10():352. PubMed ID: 22152094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality assessment of common anti-malarial medicines marketed in Gambella, National Regional State, South Western-Ethiopia.
    Ahmed F; Eticha T; Ashenef A
    Malar J; 2024 Sep; 23(1):278. PubMed ID: 39272079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi.
    Khuluza F; Kigera S; Heide L
    Am J Trop Med Hyg; 2017 May; 96(5):1124-1135. PubMed ID: 28219993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the effectiveness of the CD3+ tool to detect counterfeit and substandard anti-malarials.
    Batson JS; Bempong DK; Lukulay PH; Ranieri N; Satzger RD; Verbois L
    Malar J; 2016 Feb; 15():119. PubMed ID: 26917250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An empirical review of antimalarial quality field surveys: the importance of characterising outcomes.
    Grech J; Robertson J; Thomas J; Cooper G; Naunton M; Kelly T
    J Pharm Biomed Anal; 2018 Jan; 147():612-623. PubMed ID: 28549854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence.
    Karunamoorthi K
    Malar J; 2014 Jun; 13():209. PubMed ID: 24888370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries.
    Hauk C; Hagen N; Heide L
    Am J Trop Med Hyg; 2021 Mar; 104(5):1936-1945. PubMed ID: 33788775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combating poor-quality anti-malarial medicines: a call to action.
    Bassat Q; Tanner M; Guerin PJ; Stricker K; Hamed K
    Malar J; 2016 Jun; 15():302. PubMed ID: 27251199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic impact of substandard and falsified antimalarial medications in Nigeria.
    Beargie SM; Higgins CR; Evans DR; Laing SK; Erim D; Ozawa S
    PLoS One; 2019; 14(8):e0217910. PubMed ID: 31415560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?
    Walker EJ; Peterson GM; Grech J; Paragalli E; Thomas J
    BMC Public Health; 2018 May; 18(1):630. PubMed ID: 29764407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa.
    Nayyar GM; Breman JG; Newton PN; Herrington J
    Lancet Infect Dis; 2012 Jun; 12(6):488-96. PubMed ID: 22632187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor-quality antimalarials further health inequities in Uganda.
    Evans DR; Higgins CR; Laing SK; Awor P; Ozawa S
    Health Policy Plan; 2019 Dec; 34(Supplement_3):iii36-iii47. PubMed ID: 31816072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model.
    Jackson KD; Higgins CR; Laing SK; Mwila C; Kobayashi T; Ippolito MM; Sylvia S; Ozawa S
    BMC Public Health; 2020 Jul; 20(1):1083. PubMed ID: 32646393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The quality of veterinary medicines and their implications for One Health.
    Vidhamaly V; Bellingham K; Newton PN; Caillet C
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35918072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor-quality medicines: from knowledge to control and prevention.
    Ravinetto RM
    Pathog Glob Health; 2014 Jun; 108(4):171-2. PubMed ID: 24954880
    [No Abstract]   [Full Text] [Related]  

  • 20. Usefulness of combined screening methods for rapid detection of falsified and/or substandard medicines in the absence of a confirmatory method.
    Opuni KF; Nettey H; Larbi MA; Amartey SNA; Nti G; Dzidonu A; Owusu-Danso P; Owusu NA; Nyarko AK
    Malar J; 2019 Dec; 18(1):403. PubMed ID: 31805937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.